drugset / Trial / NCT03943238

TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation

NCT03943238 ↗

NaSingle-groupOpen-labelTreatment

Summary

This study will determine whether a preparatory regimen including total lymphoid irradiation (TLI), total body irradiation (TBI), anti-thymocyte globulin (ATG) and infusion of the donor hematopoietic stem cells when given along with recipient regulatory T cells (Tregs) will allow for eventual discontinuation of anti-rejection drugs after living donor kidney transplantation.

Timeline

Start
2020-02-01
Primary completion
2029-11-01
Completion
2029-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Donor CD34+ Unknown 1e+07 cells/kg —
Subject donor T cell Unknown 1e+08 cells/kg —
Subject recipient Tregs Unknown 2.5e+07 cells/kg —

Indications

No indication recorded.